Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
Laura Bartels-Peculis,1 Ajay Sharma,2 Alison M Edwards,2 Anirudh Sanyal,2 Erin Connolly-Strong,1 Winnie W Nelson1 1Mallinckrodt Pharmaceuticals, Inc., Bedminster, NJ, USA; 2Healthagen LLC, New York, NY 10017, USACorrespondence: Laura Bartels-Peculis Email laura.bartels@mnk.comObjective: To describe...
Guardado en:
Autores principales: | Bartels-Peculis L, Sharma A, Edwards AM, Sanyal A, Connolly-Strong E, Nelson WW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a65a16b78114d8ab20e88b0ccc6d608 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of refractory lupus nephritis: challenges and solutions
por: Yo JH, et al.
Publicado: (2019) -
Potential serum and urine biomarkers in patients with lupus nephritis and the unsolved problems
por: Hsieh SC, et al.
Publicado: (2016) -
Old and New Calcineurin Inhibitors in Lupus Nephritis
por: Claudio Ponticelli, et al.
Publicado: (2021) -
The Role of NLRP3 Inflammasome in Lupus Nephritis
por: Camila Barbosa Oliveira, et al.
Publicado: (2021) -
Psychological State and Associated Factors During the 2019 Coronavirus Disease (COVID-19) Pandemic Among Filipinos with Rheumatoid Arthritis or Systemic Lupus Erythematosus
por: Tee CA, et al.
Publicado: (2020)